HT
ACAD icon

Headlands Technologies’s Acadia Pharmaceuticals ACAD Stock Holding History

Headlands Technologies’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$541K Buy
+24,296
New +$581K 0.06% 340
2025
Q2 		– Sell
-13,341
Closed -$222K – 1147
2025
Q1 		$222K Sell
13,341
-34,916
-72% -$634K 0.03% 439
2024
Q4 		$886K Buy
48,257
+3,619
+8% +$58.4K 0.09% 234
2024
Q3 		$687K Sell
44,638
-12,571
-22% -$210K 0.08% 271
2024
Q2 		$930K Buy
57,209
+54,608
+2,100% +$881K 0.1% 180
2024
Q1 		$48.1K Buy
+2,601
New +$64.4K 0.01% 732
2023
Q3 		– Sell
-5,562
Closed -$133K – 890
2023
Q2 		$133K Buy
+5,562
New +$124K 0.04% 342

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Headlands Technologies's ACAD Position: Q1 2026 in Review

Headlands Technologies opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 24,296 shares worth $541K. The stake represents 0.06% of the portfolio and ranks #340 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in ACAD as recently as Q1 2025.

Headlands Technologies first reported a position in ACAD in Q2 2023 and has held it in 7 quarters since. The position peaked at $930K in Q2 2024. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Headlands Technologies held 24,296 shares of Acadia Pharmaceuticals worth $541K as of Q1 2026.
  • Acadia Pharmaceuticals was a new Headlands Technologies position in Q1 2026.
  • Acadia Pharmaceuticals made up 0.06% of Headlands Technologies's portfolio in Q1 2026, its #340 holding.
  • Headlands Technologies first reported a position in Acadia Pharmaceuticals in Q2 2023 and has held it in 7 quarters since.
  • Headlands Technologies's Acadia Pharmaceuticals position peaked at $930K in Q2 2024.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.